CCA
BIO icon

Criterion Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Criterion Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$7.37K Hold
27
– – ﹤0.01% 274
2024
Q3 		$7.37K Hold
27
– – ﹤0.01% 274
2024
Q2 		$7.37K Hold
27
– – ﹤0.01% 274
2024
Q1 		$9.34K Hold
27
– – 0.01% 264
2023
Q4 		$8.72K Buy
+27
New +$8.46K 0.01% 271

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Criterion Capital Advisors's BIO Position: Q4 2024 in Review

Criterion Capital Advisors held its Bio-Rad Laboratories Class A (BIO) position steady in Q4 2024 at 27 shares worth $7.37K. The position accounts for ﹤0.01% of the portfolio, ranked #274.

Criterion Capital Advisors first reported a position in BIO in Q4 2023 and has held it in 5 quarters since. The position peaked at $9.34K in Q1 2024. 456 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

  • Criterion Capital Advisors held 27 shares of Bio-Rad Laboratories Class A worth $7.37K as of Q4 2024.
  • Criterion Capital Advisors left its Bio-Rad Laboratories Class A share count unchanged in Q4 2024.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Criterion Capital Advisors's portfolio in Q4 2024, its #274 holding.
  • Criterion Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and has held it in 5 quarters since.
  • Criterion Capital Advisors's Bio-Rad Laboratories Class A position peaked at $9.34K in Q1 2024.
  • 456 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Criterion Capital Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.